Company Information

    Monta Biosciences was founded on January 2014. The company is based in Denmark, SC, USA . The number of employees in Monta biosciences is less than 50. Monta biosciences is a start-up biotech company located in the science park of the largest university park in denmark.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Monta biosciences has received 2 rounds of venture funding. The total funding amount is around $3.7M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Monta biosciences - Blog

                          • MonTa Biosciences successfully dose first patient in phase I clinical trial

                          • MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase I clinical trial. Our drug MBS8 is a novel type of cancer immunotherapy with a Mode of Action not previously seen in cancer therapy was infused over one hour, and the patient managed the treatment very well. The study is [...]Indlægget MonTa Biosciences successfully dose first patient in phase I clinical trial blev først udgivet på montabiosciences.com.
                          • MonTa Biosciences awarded approval from regulatory agencies to start phase I study

                          • MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate phase I study on our lead candidate MBS8. The study will start later in Q1 with dosing of solid tumor patients in a dose-escalation study. The primary endpoint is to establish the recommended phase 2 dose level, for which the [...]Indlægget MonTa Biosciences awarded approval from regulatory agencies to start phase I study blev først udgivet på montabiosciences.com.
                          • MonTa Biosciences becomes a Clinical Stage Company

                          • MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical stage Biotech company. MonTa has today filed our first Clinical Trial Application in Europe and look forward to start treatment of the first patient with our lead candidate MBS8, in Q1, 2021. We will start the dose-escalation part of the [...]Indlægget MonTa Biosciences becomes a Clinical Stage Company blev først udgivet på montabiosciences.com.
                          • MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program

                          • MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the Nanotechnology Characterization Laboratory (NCL) program under the National Cancer Institute (NCI) in the US. Our lead candidate MBS8 has been selected for the NCL program where NCL free of charge will support MonTa with additional Mode of Action studies to [...]Indlægget MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program blev først udgivet på montabiosciences.com.
                          • MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency

                          • MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views on development strategy and interpretation of ICH guidelines. MonTas plan for moving our lead candidate MBS8 into the clinic was well supported, securing a clear path forward toward, and a smooth process for our Clinical Trial Application filed in the [...]Indlægget MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency blev først udgivet på montabiosciences.com.
                          • MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development

                          • Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong record of bringing oncology products forward into clinical development. Steven will be supporting MonTa in the clinical development of MBS8 which is planned to enter clinical trial by the end of 2020. The board and management of MonTa Biosciences are [...]Indlægget MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development blev først udgivet på montabiosciences.com.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *